PERSPECTIVAS PARA A TERAPÊUTICA FARMACOLÓGICA DAS ARRITMIAS VENTRICULARES
|
(especial para SIIC © Derechos reservados) |
|
Apesar da evidência de superioridade dos CDI, a terapêutica antiarrítmica deverá manter uma posição central no tratamento das arritmias e deverão desenvolver-se cada vez mais, as terapêuticas híbridas. |
Clasificación en siicsalud
Artículos originales> Expertos del Mundo>
página www.siicsalud.com/des/des029/02823000.htm
Especialidades
Principal: Cardiología
Relacionadas: Medicina Interna, Farmacología
Artículo completo
(portugués)
Extensión:
+/- 7.63 páginas impresas en papel A4
Exclusivo para suscriptores/ assinantes |
Bibliografía del artículo
- Julian DG, Camm AJ, Frangin G et al, for the European Myocardial Infarct Amiodarone Trial Investigators.Randomized trial of the effect of amiodarone on mortality in patients with left-ventricular dysfuction after myocardial infarction: EMIAT. Lancet 1997; 349:667-74
- Cairns J, Connolly S, Roberts R, Gent M for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet1997; 349:675-82
- Domanski MJ, Sakseena S, Epstein AE, et al. for the AVID investigators. Relative effectiveness of the implantable cardioversos and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. J Am Col Cardiol 1999; 34: 1090-5
- Strictberger SA. Progress in Clinical Trials: Amiodarona vs implantable defibrillator in patients with nonischemic cardiomyophathy and asymptomatic non-sustained ventricular tachycardia (AMIOVIRT). Clin Cardiol 2001; 24:85-8
- Steinberg JS, Martins J, Sadanandan S et al. for the AVID investigators. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics versus Implantable Defibrillators (AVID) Study. Am Heart J 2001; 142:520-9
- Rosen MR. Antiarrhythmic drugs: Rethinking targets, developmente strategies and evaluation tools. Am J Cardiol 1998; 81(6A):21D-23D
- Nattel S. The molecular and ionic specificity of antiarrhythmic drugs actions. J Cardiovasc Electrophysiol, 1999; 10: 272-82
- Camm AJ, Yap YG. What should we expect from the next generation of antiarrhythmic drugs. J Cardiovasc Electrophysiol, 1999; 10: 307-17
- Members of the Sicilian Gambit. New approaches to antiarrhythmic therapy. Emerging therapeutic applications of the cell biology of cardiac arrhythmias. Eur Heart J 2001;22: 2148-63
- Hancox JC, Patel KCR, Jones JV. Antiarrhythmics - from cell to clinic: past, present and future. Heart 2000; 84: 14-24
- Tamargo J, Déplon E. Farmacologfia Clínica de los nuevos medicamentos antiarrítmicos. Rev Port Cardiol 2001; 20:887-98
- Singh BN Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol, 1999; 10: 283-301
|
|
|
©
Está
expresamente prohibida la redistribución y la redifusión de todo o parte de los
contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin
previo y expreso consentimiento de SIIC. |
|
|
